The Company's lead oral product candidates are PTG-100 for ulcerative colitis, which is under phase 2b trial, and PTG-200 for Crohn's disease, which is under phase I testing.

Also in the pipeline is PTG-300, an injectable hepcidin mimetic peptide for potential treatment of chronic iron overload in rare diseases such as beta-thalassemia, which recently completed phase I testing. The Company plans to initiate Phase 2 trials of PTG-300 in patients with beta-thalassemia and myelodysplastic syndrome during 2018.Protagonist retains worldwide commercial rights to the PTG-100 and PTG-300 programs. PTG-200 is partnered with Janssen Biotech.

Upcoming event:

-- The Company is slated to provide a corporate overview on February 14 at 9:30 am Eastern Time at the Leerink Partners 7th Annual Global Healthcare Conference.

-- On January 5, 2018, the Company reported top line results from its two phase III clinical trials, dubbed STRIDE 1 and STRIDE 2, evaluating KPI-121 0.25% in patients with dry eye disease.

There was statistically significant improvement in ocular discomfort, the primary symptom endpoint, in STRIDE 1 but not in STRIDE 2. The STRIDE 1 and STRIDE 2 trials achieved statistical significance for the primary sign endpoint of conjunctival hyperemia change.

Near-term Catalysts:

-- The New Drug Application for Inveltys for post surgical pain and inflammation is under FDA review, with a decision expected on August 24, 2018.

-- On Feb.2, 2018, the Company announced the resignation of Sarah Noonberg, the Company's Chief Medical Officer.

Near-term Catalysts:

-- Top-line results from a phase IIb study of NEOD001 in previously treated subjects with light chain (AL) Amyloidosis, dubbed PRONTO, are expected in the second quarter of 2018.-- Clinical development of PRX004 for the treatment of ATTR amyloidosis is expected to begin around mid-2018.-- A phase II study of PRX002/RG7935 for the treatment of Parkinson's disease, initiated in the second quarter of 2017, is underway.

-- The FDA decision on resubmitted New Drug Application for Apadaz, an investigational product candidate that is intended to provide short-term management of acute pain, is expected on February 23, 2018.-- A pivotal efficacy trial of KP415 for the treatment of Attention Deficit, Hyperactivity Disorder is underway, with top line data anticipated in mid-2018, and complete data set expected to be available prior to the end of the year.